Head-to-head · WeighScore
Found vs Hims & Hers
The verdict
Found takes it — 83.5/100 to 75.6/100.
Found grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. The broadest medication bench in the ranking — compounded, brand-name and oral orforglipron — priced off a membership rather than a sticker.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Found | Hims & Hers |
|---|---|---|
| WeighScore | 83.5/100 | 75.6/100 |
| Grade | B | C |
| Scorecard rank | #12 | #53 |
| Semaglutide | $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); the advertised $99 is the in-network INSURANCE rate and still precedes a ~$30 per-visit copay | $199/mo |
| Tirzepatide | $289/mo cash month-to-month · $169/mo on a 12-month prepay paid up front ($2,028); one program price covers both molecules | Not disclosed |
| Coverage | All 50 states | All 50 states |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #12 · B
Strengths
- Widest medication list in this ranking — compounded semaglutide and tirzepatide, brand Wegovy, Zepbound, Ozempic, Mounjaro, Saxenda and Victoza, plus oral Foundayo (orforglipron) and Rybelsus
- Flat pricing as the dose increases, so a titration does not raise the monthly cost
- Bills insurance for the clinical visits — the site states most members pay under $30 per visit
- Runs a dedicated GLP-1 microdose program for people who want a lower starting dose
Where it loses points
- The $99/mo headline is a longer-plan floor — Found's own FAQ says 3, 6 and 12-month plans are what keep the monthly cost down, so month-to-month costs meaningfully more
- Medication cost is separate from the membership and clinical care, so no advertised figure is the all-in number
- The homepage insurance selector lists roughly 41 states, not 50 — coverage is narrower than the service footprint
- Compounded medication is not FDA-approved the way brand Wegovy or Zepbound are
Graded #53 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
Where it loses points
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 509 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.